ASX Quarterly Wrap: Dimerix sees strong kidney drug trial recruitment, Prescient advances cancer therapy
It’s the quarterly season again as the ASX market announcements page becomes increasingly flooded with...
It’s the quarterly season again as the ASX market announcements page becomes increasingly flooded with...
Stockhead’s resident health and biotech expert Tim Boreham is putting down the microscope and picking up...
Victoria has a mature, internationally recognised and thriving ecosystem that supports research and translation of...
The prestigious International Society of Cell and Gene Therapy (ISCT) will showcase two abstracts from Prescient...
We can profile the patient, find out what they need, we pull the appropriate targeting...
Prescient Therapeutics Ltd (ASX:PTX) CEO Steven Yatomi-Clarke updates Proactive’s Elisha Newell after the biotech showcased pre-clinical...
Clinical stage oncology company Prescient Therapeutics (ASX: PTX) presented exciting new data on their OmniCAR...
Prescient was pleased to present data on our cell therapies at the prestigious International Society...
Clinical stage oncology company Prescient Therapeutics (ASX: PTX) has appointed highly experienced US biotech executive...
Prescient Therapeutics (ASX: PTX) -- a publicly listed oncology company developing targeted and cell therapies...

This investor centre was built by Reach Markets
©2026 Reach Markets
To stay up to date with Prescient Therapeutics news and events, please register your details.